RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/28917156http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/28917156http://www.w3.org/2000/01/rdf-schema#comment"Fms-like tyrosine kinase 3 (FLT3) is highly expressed in mixed-lineage leukemia (MLL) gene-rearranged acute lymphoblastic leukemia (MLL+ALL) with a dismal prognosis. We previously reported that FLT3 ligand (FL) stimulation induced cell cycle arrest in MLL+ALL cells leading to resistance against anti-leukemic agents. Given that FL stimulation enhanced transforming growth factor (TGF)β1 mRNA levels in MLL+ALL cells, we extensively examined the effect of TGFβ1 on the cell cycle progression and chemosensitivity in MLL+ALL cells, and found that TGFβ1 stimulation induced MLL+ALL cells into cell cycle arrest resistant to arabinosyl cytosine; its effect was markedly enhanced in synergy with FL. Thus, it is likely that TGFβ1 and FL, both abundantly produced by bone marrow stromal cells, function in a coordinated manner to render MLL+ALL cells chemoresistant, which should lead to the development of minimal residual disease (MRD) resulting in relapse. The use of inhibitors against FLT3 and TGFβ1 may become a useful strategy for eradicating MRD in MLL+ALL."xsd:string
http://purl.uniprot.org/citations/28917156http://purl.org/dc/terms/identifier"doi:10.1016/j.leukres.2017.08.013"xsd:string
http://purl.uniprot.org/citations/28917156http://purl.uniprot.org/core/author"Abe M."xsd:string
http://purl.uniprot.org/citations/28917156http://purl.uniprot.org/core/author"Ando N."xsd:string
http://purl.uniprot.org/citations/28917156http://purl.uniprot.org/core/author"Inukai T."xsd:string
http://purl.uniprot.org/citations/28917156http://purl.uniprot.org/core/author"Furuichi Y."xsd:string
http://purl.uniprot.org/citations/28917156http://purl.uniprot.org/core/author"Ichikawa H."xsd:string
http://purl.uniprot.org/citations/28917156http://purl.uniprot.org/core/author"Tamai M."xsd:string
http://purl.uniprot.org/citations/28917156http://purl.uniprot.org/core/author"Sugita K."xsd:string
http://purl.uniprot.org/citations/28917156http://purl.uniprot.org/core/author"Kasai S."xsd:string
http://purl.uniprot.org/citations/28917156http://purl.uniprot.org/core/author"Goi K."xsd:string
http://purl.uniprot.org/citations/28917156http://purl.uniprot.org/core/author"Kagami K."xsd:string
http://purl.uniprot.org/citations/28917156http://purl.uniprot.org/core/author"Harama D."xsd:string
http://purl.uniprot.org/citations/28917156http://purl.uniprot.org/core/date"2017"xsd:gYear
http://purl.uniprot.org/citations/28917156http://purl.uniprot.org/core/name"Leuk Res"xsd:string
http://purl.uniprot.org/citations/28917156http://purl.uniprot.org/core/pages"68-76"xsd:string
http://purl.uniprot.org/citations/28917156http://purl.uniprot.org/core/title"TGFbeta1 synergizes with FLT3 ligand to induce chemoresistant quiescence in acute lymphoblastic leukemia with MLL gene rearrangements."xsd:string
http://purl.uniprot.org/citations/28917156http://purl.uniprot.org/core/volume"61"xsd:string
http://purl.uniprot.org/citations/28917156http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/28917156
http://purl.uniprot.org/citations/28917156http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/28917156
http://purl.uniprot.org/uniprot/#_A0A078BBI5-mappedCitation-28917156http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/28917156
http://purl.uniprot.org/uniprot/#_A0A078BC11-mappedCitation-28917156http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/28917156
http://purl.uniprot.org/uniprot/#_A0A078BCJ0-mappedCitation-28917156http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/28917156
http://purl.uniprot.org/uniprot/#_A0A078BCH8-mappedCitation-28917156http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/28917156